CytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1)

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability